ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025

blonca9
Dec 8, 2024
1 min read

He comments on data at ASH including tafasitamab, axitilimab, and the company's BET inhibitor. Plus, news from yesterday on Incyte's PD1, and looking forward to next year.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight